This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.
Macrophages present a central line of defense against cancer by preventing inflammation and eliminating tumor cells. However, tumor-associated-macrophages (TAMs) at times protect the tumor from immune responses and facilitate its growth. Elevated levels of TAMs are commonly associated with poor outcomes, and depleting them can prevent cancer progression and metastasis. However, the signals mediating these opposing macrophage identities are unknown. Dr. Duttke aims to figure out what makes TAMs different from normal, anti-cancer macrophages by analyzing macrophages/TAMs in tumors and healthy patient tissues. Understanding the pathways linked to TAM identity may single out targets for therapies aiming to suppress TAMs and aid tumor elimination.
University of California, San Diego | All Cancers, Lung Cancer | 2015 | Christopher K. Glass, M.D., Ph.D.
Contact Us
Cancer Research Institute | National Headquarters 29 Broadway, Floor 4 | New York, NY 10006-3111
(800) 992-2623(212) 832-9376Staff Directory
July is Sarcoma Awareness Month. As a rare and difficult-to-treat form of cancer, effective drug treatments are urgently needed and immunotherapy for sarcoma shows promise.
Dr. Joan Levy, director of research at the Chordoma Foundation, discusses the current state of chordoma research and the recently launched partnership with CRI.